STERIS plc (Ireland) Ordinary Shares (STE): Price and Financial Metrics


STERIS plc (Ireland) Ordinary Shares (STE)

Today's Latest Price: $188.76 USD

0.43 (0.23%)

Updated Jan 22 7:00pm

Add STE to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 186 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

STE Stock Summary

  • STE has a market capitalization of $16,105,759,373 -- more than approximately 87.11% of US stocks.
  • STE's went public 5.23 years ago, making it older than just 17.99% of listed US stocks we're tracking.
  • The volatility of STERIS plc's share price is greater than that of merely 19.59% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to STERIS plc are SNN, COO, TFX, BRO, and PNR.
  • STE's SEC filings can be seen here. And to visit STERIS plc's official web site, go to www.steris.com.

STE Stock Price Chart Interactive Chart >

Price chart for STE

STE Price/Volume Stats

Current price $188.76 52-week high $203.90
Prev. close $188.33 52-week low $105.69
Day low $187.06 Volume 402,300
Day high $189.54 Avg. volume 499,593
50-day MA $190.09 Dividend yield 0.85%
200-day MA $168.76 Market Cap 16.11B

STERIS plc (Ireland) Ordinary Shares (STE) Company Bio


Steris Corporation develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and procedural support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The company was founded in 1985 and is based in Mentor, Ohio.

STE Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$188.76$126.01 -33%

Below please find a table outlining a discounted cash flow forecast for STE, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that STERIS plc ranked in the 42th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of STERIS plc, consider:

  • The company's debt burden, as measured by earnings divided by interest payments, is 14.92; that's higher than 75.77% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than merely 20.6% of the free cash flow producing stocks we're observing.
  • STE's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 40.11% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-34%
1%-34%
2%-33%
3%-32%
4%-32%
5%-31%

Want more companies with a valuation profile/forecast similar to that of STERIS plc? See QDEL, AMGN, NVS, ADUS, and MEDP.


STE Latest News Stream


Event/Time News Detail
Loading, please wait...

STE Latest Social Stream


Loading social stream, please wait...

View Full STE Social Stream

Latest STE News From Around the Web

Below are the latest news stories about STERIS plc that investors may wish to consider to help them evaluate STE as an investment opportunity.

STERIS to Host a Conference Call for Fiscal 2021 Third Quarter Financial Results on February 3, 2021 - Stocks News Feed

DUBLIN, IRELAND, Jan. 19, 2021 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 third quarter financial results at 10:00 a.m. ET on Wednesday, February 3, 2021. The conference call can be heard live at www.steris-ir.com or via phone… Read More »STERIS to Host a Conference Call for Fiscal 2021 Third Quarter Financial Results on February 3, 2021

Stocks News Feed | January 19, 2021

STERIS to Host a Conference Call for Fiscal 2021 Third Quarter Financial Results on February 3, 2021

DUBLIN, IRELAND, Jan. 19, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 third quarter financial results at 10:00 a.m. ET on Wednesday, February 3, 2021. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing third quarter financial results will be issued after the U.S. market closes on Tuesday, February 2, 2021. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on February 3, 2021, either at www.steris-ir.com or via phone. To access the replay...

Yahoo | January 19, 2021

Calculating The Fair Value Of STERIS plc (NYSE:STE)

Today we will run through one way of estimating the intrinsic value of STERIS plc ( NYSE:STE ) by taking the expected...

Yahoo | January 18, 2021

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Cantel Medical Corp. Buyout

WILMINGTON, Del., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Cantel Medical Corp. (“Cantel”) (NYSE: CMD) regarding possible breaches of fiduciary duties and other violations of law related to Cantel’s agreement to be acquired by STERIS plc (“STERIS”) (NYSE: STE). Under the terms of the agreement, Cantel’s shareholders will receive approximately $16.93 in cash and 0.33787 of a share of STERIS per share. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-cantel-medical-corp.You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected] Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on b...

Yahoo | January 14, 2021

Steris To Buy Rival Cantel Medical For $3.6B

Steris has agreed to snap up peer Cantel Medical Corp in a cash and stock deal valued at $3.6 billion, in what marks another consolidation move in the healthcare sector. Under the terms of the agreement, Steris (STE) has offered to pay $84.66 per Cantel common share, based on Steris’ closing share price of $200.46 on Jan. 11. Cantel stockholders will get about $16.93 in cash and 0.33787 of a Steris ordinary share for each Cantel share they own. Cantel shares closed at $83.87 on Jan. 12. The deal translates into a total enterprise value of about $4.6 billion, including Cantel’s net debt and convertible notes.

Sharon Wrobel on TipRanks | January 13, 2021

Read More 'STE' Stories Here

STE Price Returns

1-mo N/A
3-mo 1.46%
6-mo 20.70%
1-year 25.92%
3-year 112.07%
5-year 189.55%
YTD -0.41%
2020 25.50%
2019 44.09%
2018 23.66%
2017 31.73%
2016 -9.14%

STE Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full STE Dividend History

Continue Researching STE

Here are a few links from around the web to help you further your research on STERIS plc's stock as an investment opportunity:

STERIS plc (STE) Stock Price | Nasdaq
STERIS plc (STE) Stock Quote, History and News - Yahoo Finance
STERIS plc (STE) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9044 seconds.